In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)

开始日期2025-03-01

申办/合作机构

King's College London

NCT06270303 / Not yet recruitingN/AIIT

The Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects - a Multi-center Randomized Controlled Trial

The aim of this randomized clinical trial is to evaluate the potential benefit of the use of a bone substitute material in the treatment of furcation degree II-involved molars. The main question it aims to answer is: What is the benefit of the adjunctive use of a bone substitute material in the surgical treatment of furcation degree II-involved molars when compared to open-flap debridement alone?
200 patients with ≥1 molar presenting with a furcation defect degree II will be included and randomized to either control (open-flap debridement) or test treatment (open-flap debridement + bone substitute material). The primary outcome of the study is furcation closure defined as absence of clinically detectable furcation involvement degree >I. Secondary outcomes include changes in bleeding on probing, probing depth, vertical and horizontal attachment levels, soft tissue level, marginal bone level, need for surgical retreatment, tooth loss, patient-reported outcomes and adverse events. A composite outcome based on furcation closure (degree ≤I) in combination with shallow probing depth (≤5 mm) and absence of bleeding on probing will also be evaluated.

开始日期2024-12-01

申办/合作机构

University of Gothenburg

[+5]

NCT06666504 / Not yet recruitingN/AIIT

The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab (the TezEx Study): a Retrospective and Prospective Observational Study

Tezepelumab is a treatment that is approved by NICE (National Institute for Health and Care Excellence, https://www.nice.org.uk/) for patients with severe asthma, that remains poorly controlled despite high dose inhaled glucocorticosteroid medication.
The goal of this observational study is to learn why some patients with severe asthma continue to have asthma flare ups despite being on tezepelumab.

开始日期2024-12-01

申办/合作机构

King's College London

100 项与 King's College London 相关的临床结果

登录后查看更多信息

0 项与 King's College London 相关的专利（医药）

登录后查看更多信息

76,257

项与 King's College London 相关的文献（医药）

2025-01-01·ADDICTIVE BEHAVIORS

Does Self-Reported smoking cessation fatigue predict making quit attempts and sustained abstinence among adults who smoke Regularly?

Article

作者: Cummings, K. Michael ; Nottage, Matilda K. ; Sheffer, Christine E ; Cea, Claudia M ; Cummings, K Michael ; Sheffer, Christine E. ; Borland, Ron ; Yong, Hua-Hie ; Nottage, Matilda K ; Cea, Claudia M. ; Michael Cummings, K.

BACKGROUND:

Quitting smoking is difficult and many people who smoke experience cessation fatigue (CF) as a result of multiple failed attempts. This study examined the association of CF with making and sustaining a smoking quit attempt.

METHODS:

Data analysed were 4,139 adults (aged 18 years or older) who smoked daily or weekly and participated in the 2018 and 2020 International Tobacco Control Four Country Smoking and Vaping Surveys (ITC 4CV) conducted in Australia, Canada, England, and the US. CF was assessed at baseline using a single question: "To what extent are you tired of trying to quit smoking?" with response options: "Not at all tired"; "Slightly tired"; "Moderately tired"; "Very tired"; or "Extremely tired". We used binary logistic regression models to test the hypothesis that baseline CF would predict lower odds of both making a quit attempt and sustaining abstinence for a month or longer at follow-up adjusted for socio-demographic and smoking/vaping-related covariates.

RESULTS:

Persons who currently smoked and reported at least some CF were more likely to make a quit attempt, but less likely to sustain abstinence for at least one month, than those who reported no CF. These associations were independent of socio-demographic variables, and they did not differ by country.

CONCLUSION:

Contrary to expectation, CF was positively associated with making a quit attempt and non-linearly associated with lower rates of sustained abstinence at follow-up. While these findings should be replicated, they suggest that people with CF may benefit from targeted support to remain abstinent after a quit attempt.

2025-01-01·MEDICAL IMAGE ANALYSIS

Enhancing global sensitivity and uncertainty quantification in medical image reconstruction with Monte Carlo arbitrary-masked mamba

Article

作者: Schönlieb, Carola-Bibiane ; Shi, Kuangyu ; Huang, Jiahao ; Nan, Yang ; Wu, Weiwen ; Yang, Liutao ; Aviles-Rivero, Angelica I ; Wu, Yinzhe ; Zhang, Daoqiang ; Yang, Guang ; Aviles-Rivero, Angelica I. ; Wang, Chengyan ; Wang, Fanwen

Deep learning has been extensively applied in medical image reconstruction, where Convolutional Neural Networks (CNNs) and Vision Transformers (ViTs) represent the predominant paradigms, each possessing distinct advantages and inherent limitations: CNNs exhibit linear complexity with local sensitivity, whereas ViTs demonstrate quadratic complexity with global sensitivity. The emerging Mamba has shown superiority in learning visual representation, which combines the advantages of linear scalability and global sensitivity. In this study, we introduce MambaMIR, an Arbitrary-Masked Mamba-based model with wavelet decomposition for joint medical image reconstruction and uncertainty estimation. A novel Arbitrary Scan Masking (ASM) mechanism "masks out" redundant information to introduce randomness for further uncertainty estimation. Compared to the commonly used Monte Carlo (MC) dropout, our proposed MC-ASM provides an uncertainty map without the need for hyperparameter tuning and mitigates the performance drop typically observed when applying dropout to low-level tasks. For further texture preservation and better perceptual quality, we employ the wavelet transformation into MambaMIR and explore its variant based on the Generative Adversarial Network, namely MambaMIR-GAN. Comprehensive experiments have been conducted for multiple representative medical image reconstruction tasks, demonstrating that the proposed MambaMIR and MambaMIR-GAN outperform other baseline and state-of-the-art methods in different reconstruction tasks, where MambaMIR achieves the best reconstruction fidelity and MambaMIR-GAN has the best perceptual quality. In addition, our MC-ASM provides uncertainty maps as an additional tool for clinicians, while mitigating the typical performance drop caused by the commonly used dropout.

2025-01-01·MEDICAL IMAGE ANALYSIS

Fetal body organ T2* relaxometry at low field strength (FOREST)

Article

作者: Deprez, Maria ; Rutherford, Mary A. ; Aviles Verdera, Jordina ; Egloff, Alexia ; Hajnal, Joseph V. ; Hajnal, Joseph V ; Story, Lisa ; Verdera, Jordina Aviles ; Tomi-Tricot, Raphaël ; Uus, Alena U ; Payette, Kelly ; Rutherford, Mary A ; Hutter, Jana ; Hall, Megan ; Uus, Alena U.

Fetal Magnetic Resonance Imaging (MRI) at low field strengths is an exciting new field in both clinical and research settings. Clinical low field (0.55T) scanners are beneficial for fetal imaging due to their reduced susceptibility-induced artifacts, increased T2* values, and wider bore (widening access for the increasingly obese pregnant population). However, the lack of standard automated image processing tools such as segmentation and reconstruction hampers wider clinical use. In this study, we present the Fetal body Organ T2* RElaxometry at low field STrength (FOREST) pipeline that analyzes ten major fetal body organs. Dynamic multi-echo multi-gradient sequences were acquired and automatically reoriented to a standard plane, reconstructed into a high-resolution volume using deformable slice-to-volume reconstruction, and then automatically segmented into ten major fetal organs. We extensively validated FOREST using an inter-rater quality analysis. We then present fetal T2* body organ growth curves made from 100 control subjects from a wide gestational age range (17-40 gestational weeks) in order to investigate the relationship of T2* with gestational age. The T2* values for all organs except the stomach and spleen were found to have a relationship with gestational age (p<0.05). FOREST is robust to fetal motion, and can be used for both normal and fetuses with pathologies. Low field fetal MRI can be used to perform advanced MRI analysis, and is a viable option for clinical scanning.

182

项与 King's College London 相关的新闻（医药）

2024-10-23

·梅斯医学

轻轻一电，改善抑郁症？《自然-医学》：缓解率高出2倍之多

抑郁症是导致全球范围内残疾的主要原因之一，一线治疗策略是抗抑郁药联合心理治疗。临床上，超过1/3的抑郁症患者治疗后未能实现完全临床缓解。经颅直流电刺激（tDCS）是一种非侵入性脑刺激技术，通过置于头皮的两个或多个电极产生微弱直流电，来调节大脑皮质兴奋性。 ▲tDCS系统示意图（图片来源：参考文献[2]）既往研究发现，便携式的tDCS安全且耐受性良好，是抑郁症的潜在新一线治疗方案。但通常tDCS治疗需要连续治疗几周，且多数研究均在研究所开展，需要参与者每天接受访视，这在一定程度上限制了其临床应用前景。此外，既往已开展的研究纳入患者人数较少，且研究时间普遍限制在6周，仍需有大规模研究来佐证tDCS疗效。为此，来自伦敦国王学院、东伦敦大学、得克萨斯大学休斯顿健康科学中心等机构的研究团队共同开展了一项大型、双盲、随机优效性试验，结果显示，基于远程监督模式的为期10周家庭tDCS治疗抑郁症，显示出较好的疗效、可接受性和安全性，可有效缓解至少中度抑郁患者的症状。该研究发表于《自然-医学》（Nature Medicine）。研究共同作者，来自得克萨斯大学休斯顿健康科学中心的Machado-Vieira教授表示：“这项研究证实了基于家庭的tDCS在治疗抑郁症方面的安全性和积极有效性，有望帮助更多患者及时获得治疗”。截图来源：Nature Medicine 研究纳入174例抑郁症患者，其中69%为女性，至少为中度抑郁。所有患者既往未接受治疗、稳定服用抗抑郁药或接受心理治疗至少6周。基线时，汉密尔顿抑郁量表-17项（HDRS-17）评分（分数越高、病情越严重）平均分为19.07分。研究人员将患者随机纳入主动tDCS刺激组（87例）和假性tDCS刺激组（87例）。两组患者分别接受持续30分钟的2 mA直流电刺激，以及使用相同器械和应用程序进行假性刺激，假性tDCS刺激患者同样可感受到主动刺激的刺痛感，以充分模拟主动刺激。所有患者先接受为期10周的家庭环境tDCS治疗抑郁症，即每周5次，持续治疗3周，接着转为每周3次，持续治疗7周。10周家庭环境治疗结束后，进行为期10周的开放标签治疗，主动tDCS刺激组患者可继续接受每周3次的主动tDCS治疗，假性tDCS刺激组患者先接受每周5次，持续3周的主动tDCS刺激，再转为每周3次，治疗7周。整个研究过程中，研究人员均可进行远程监控，并根据机器传回的数据来判断患者操作的合规性。研究结果显示，基线至治疗第10周时，相比于假性tDCS刺激组，主动tDCS刺激组患者HDRS-17评分降低更多（9.41分 vs. 7.14分，P=0.012）。 ▲主动tDCS刺激组（蓝色圆点）和假性tDCS刺激组（黄色三角）的抑郁严重程度评分随时间的变化（图片来源：参考文献[1]）基于HDRS评分可知，主动tDCS刺激组患者临床应答率显著高于假性tDCS刺激组（58.3% vs. 37.8%，P=0.017）。主动tDCS刺激组患者缓解率高出假性tDCS刺激组2倍之多（44.9% vs. 21.8%，P=0.004）。此外，探索性分析还发现，两组患者的焦虑、轻躁狂症状均有所改善，且相比于假性tDCS刺激组，主动tDCS刺激组改善更明显。总之，这项研究表明基于家庭的tDCS可能是抑郁症的潜在一项治疗策略，其疗效高、患者可接受性强且安全性可靠。参考资料 [1] Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-03305-y [2] 唐睿, 宋洪文, 孔卓, 等. 经颅直流电刺激治疗常见神经精神疾病的临床应用专家共识[J]. 中华精神科杂志, 2022, 55(5): 327-382. DOI: 10.3760/cma.j.cn113661-20220527-00131 撰文 | 医学新视点编辑 | 阿拉斯加宝 ●大无语！夜班收了3个患者，欠费逃单跑了俩，共欠1万多！当事医生后续会被扣钱、写情况报告！公立医院不再收押金，如何保证就医诚信？ ●震撼！坐车9小时去大三甲看病，医生下班了，睡在座椅下，副主任医师心疼加号！医生：不想被道德绑架，渴望有加号、退号和拒绝就诊的权力 ●荒唐！医学生发布大体老师头骨合影至短视频平台，自称“无所畏惧”！网友怒批：轻佻无知、毫无尊重，这样搞我们以后谁还敢去捐献遗体？版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床结果

2024-10-22

·GlobeNewswire-Health Care

Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses

London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces upcoming oral and poster presentations at the 2024 European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, held in Rome, Italy (October 22-25, 2024) and at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held in San Diego, CA (November 15-19). An oral presentation at ESGCT and a poster presentation at The Liver Meeting will highlight progress of the LIBERATE study of its lead CAR-Treg candidate QEL-001 to safely induce donor-specific tolerance in liver transplant patients thereby overcoming limitations encountered with previous clinical approaches. The clinical data being presented from the safety cohort demonstrate that QEL-001 is well-tolerated, has shown cell persistence post infusion up to six months and has a stable phenotype over time via FOXP3 and HELIOS expression. In addition, analysis of liver biopsies has confirmed the trafficking, engraftment, and phenotypic stability of the QEL-001 product in the transplanted livers. Having successfully completed the safety cohort, Quell is advancing QEL-001 in the efficacy cohort of the Phase 1/2 LIBERATE clinical trial in liver transplant patients. A poster presentation at ESGCT will describe progress in developing a differentiation process to generate Treg cells from iPSC stem cells, which will enable the future development of allogenic cell therapies for autoimmune and inflammatory diseases. The in vitro characterization data demonstrates the identity, stability and functionality of the iPSC-derived Tregs, which exhibit potent suppressive activity. Quell is advancing further development of the iPSC-Treg platform in collaboration with Cellistic, a specialist in process development and manufacture of immune cell therapies based on human iPSC technology. Details of the presentations can be found below: At ESGCT (October 22-25 – abstracts available to registered attendees by clicking here) Oral presentation: Abstract Title: CAR-Treg cell therapy to induce tolerance in liver transplantation – LIBERATE clinical trialAbstract Number: OR084Date & Time: Thursday, October 24, 2024; 3:30 p.m. - 5:30 p.m. (CET)Session: 9c – Immunotherapy and CAR-T Cells IIRoom: Meeting Room 2Presenter: Rupert Kenefek, PhD, Senior Director Translational Sciences at Quell Therapeutics Poster presentation: Abstract Title: Development and characterization of iPSC-derived regulatory T cells – Towards an allogenic cell therapy for the treatment of autoimmunity and inflammatory conditionsAbstract Number: PO368Date & Time: Wednesday, October 23, 2024; 1:30 p.m. - 3:00 p.m. (CET)Session: Poster Session IIPresenter: Sophie Howson, Scientist at Quell Therapeutics At The Liver Meeting (November 15-19 – abstract available by clicking here) Poster Presentation Abstract Title: The Safety and Tolerability of QEL-001, an Autologous Chimeric Antigen Receptor (CAR) T Regulatory (Treg) Cell Therapy, in Liver Transplantation – A Safety Cohort in the LIBERATE StudyAbstract Number: 1386Date & Time: Saturday, November 16, 2024; 1:00 p.m. - 2:00 p.m. (PST)Session: Poster Session IIPresenter: Alberto Sanchez-Fueyo, Professor of Hepatology and Academic Head of the Institute of Liver Studies at King’s College London, and Honorary Transplant Hepatology Consultant at King’s College Hospital, and Co-Founder of Quell Therapeutics ### About Quell TherapeuticsQuell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aims to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system. The Company is leveraging its pioneering Foxp3 Phenotype Lock™ technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches. Quell’s lead candidate QEL-001 is advancing in the Phase 1/2 LIBERATE clinical trial designed to investigate its ability to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases internally and in partnership with AstraZeneca. www.quell-tx.com. Contacts Media: Mark Swallow, PhD, Sandi Greenwood MEDiSTRAVA Quell-Tx@Medistrava.comInvestors: Corey Davis, PhD LifeSci Advisors cdavis@lifesciadvisors.com

细胞疗法临床研究免疫疗法AACR会议

2024-10-09

·PipelineReview

Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications

Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development AviadoBio receives $20 million equity investment, up to $30 million in upfront payments and is eligible to receive up to $2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option LONDON, UK and TOKYO, Japan I October 8, 2024 I AviadoBio Ltd. (“AviadoBio”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations (FTD-GRN). FTD is a devastating form of early-onset dementia that typically leads to death within three to 13 years from diagnosis. People with FTD commonly experience a rapid decline in executive function (attention control, working memory, problem-solving etc.), uncharacteristic behaviors, loss of language, apathy, and reduced mobility. It is an important cause of dementia in those under the age of 65 and is often underrecognized, and misdiagnosed. 1,2,3,4 Under the terms of the agreement, Astellas will have the option to receive a worldwide exclusive license for the development and commercialization rights to AVB-101 in FTD-GRN and other potential indications. Astellas will make a $20 million equity investment and up to $30 million in upfront payments for the option to license AVB-101. AviadoBio is also eligible to receive up to $2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option. Lisa Deschamps, CEO, AviadoBio “As we complete dosing of the first cohort of patients in our Phase 1/2 ASPIRE-FTD trial of AVB-101, we are excited about the potential of this collaboration to help address the unmet need that exists today in frontotemporal dementia. This strategic collaboration will combine our promising gene therapy candidate for FTD-GRN and delivery expertise with Astellas’ global capabilities in development and commercialization of gene therapies. Together, we can further accelerate delivering this investigational medicine to families around the world who so desperately need treatment options for FTD-GRN and other neurological diseases.” Adam Pearson, Chief Strategy Officer, Astellas “We look forward to collaborating with the team at AviadoBio as we expand our gene therapy pipeline to help a broader range of people living with debilitating, neurodegenerative diseases. AVB-101 represents a truly innovative approach to the treatment of FTD-GRN and has the potential to be part of the next generation of gene therapy products through the creation of this agreement. Genetic regulation remains a cornerstone of our primary focus strategy at Astellas and this agreement helps us to continue to provide potential solutions for patients in need.” About AviadoBio At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with neurological conditions. With our deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, AviadoBio is working to overcome the challenges of delivering the right drug to the right place. Its innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. AviadoBio was founded on pioneering research from King’s College London and the UK Dementia Research Institute and has a leadership team with extensive gene therapy development, delivery, and commercialization experience which uniquely positions the company for success in bringing transformative medicines to patients. AviadoBio’s investors include New Enterprise Associates (NEA), Monograph Capital, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), SV Health Investor’s Dementia Discovery Fund (DDF), Advent Life Sciences, EQT Life Sciences (Dementia Fund), and LifeArc Ventures. For more information, please visit www.aviadobio.com and follow us on X @AviadoBio and LinkedIn at AviadoBio . About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ ® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en . About Astellas Gene Therapies Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Our gene therapy drug discovery engine is built around innovative science, a validated AAV platform, and industry leading internal manufacturing capability with a particular focus on rare diseases of the eye, CNS and neuromuscular system. Astellas Gene Therapies will also be advancing additional Astellas gene therapy programs toward clinical investigation. Astellas Gene Therapies is based in South San Francisco, with manufacturing and laboratory facilities in South San Francisco, Calif., Sanford, N.C. and Tsukuba, Japan. SOURCE: Astellas Pharma

引进/卖出基因疗法

100 项与 King's College London 相关的药物交易

登录后查看更多信息

100 项与 King's College London 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

IRL-201805 ( RANK x RANKL )	类风湿关节炎更多	临床2期
Rasolvir(King's College London)	类风湿关节炎更多	临床2期
LEU-001 ( EGFR )	头颈部肿瘤更多	临床2期
KCL-286 ( RARβ2 )	脊髓损伤更多	临床1期
CSPG4靶向ADC(King's College London) ( CSPG4 )	黑色素瘤更多	临床前